Micrima

REDEFINING CANCER DIAGNOSTICS USING RADIO WAVES

Confidential

Breast cancer is the most common cancer in women of **all** ages globally, with the highest mortality rate

Early detection through technology, is **critical**

500M*
Women

from puberty onwards, will experience breast cancer in their lifetime

* 12.9% of 3.9B women globally

Micrima

Mammography is today's predominant detection modality

But it has two fundamental issues

It's highly *ineffective* in *dense* tissue

X-Rays struggle to penetrate fibro glandular tissue. So screening is limited to older women, because breast density decreases with age.



It can only be used *infrequently*

Mammography uses ionising radiation, limiting frequency, commonly to just every 2-3 years. This gives cancer the opportunity to spread.

HIGHEST SCREENING **RECALL** RATES ASSOCIATED TO POOR DETECTION, IN **DENSE** TISSUE, ON 2D **MAMMOGRAMS**

Micrima

We have developed an innovative new method of breast tissue measurement (not imaging) using harmless radio waves, not X-rays.

9 patents &
UK Design Registration
(hardware and software)
2 additional patents and EU & US design registration applications pending

Measurements validated against Mammography in an MHRA approved trial at Leeds Teaching Hospital under Dr Nisha Sharma. **CE MDR pending**

- Whole breast tissue measurement
- Effective in all tissue types
- Suitable for ALL women, post puberty
- Non-invasive, pain-free
- Fast acquisition, easy to use*
- Optimises imaging pathway

*Does not need to be operated by a qualified healthcare professional

Micrima

Mi~Scan

MiScan® measures tissue responses from hundreds of frequency points, in each 1 second scan, creating a rich data set of tissue properties.

Our launch product provides an accurate breast density measurement in line with American College of Radiology (ACR) standards (BI-RADS® 4th Edition) that are adopted globally



Total procedure time of 1 minute for both breasts (including patient dressing time)
Procedure can be performed by anyone, with 30mins training

Micrima

Provides clinical and patient value

Use within Diagnostic workflow

Mi~Scan *Pending CE marking

Used in patient assessment to measure breast density

The best technique for each patient's breast tissue type can be selected first time

Personalised diagnostic pathways delivered with estimated 24% less resource and 12% less cost

Patients have one scan, experience less pain and absorb on average 26% less Mammogram radiation

Use within Screening workflow

Mi~Score *Pending CE marking



Ikonopedia®

Breast density measurement is fed into pre-validated breast cancer risk models (TC8 and BOADICEA)

MiScan® delivers significant improvement in risk model prediction, without the need for a Mammogram

Risk profiling can be deployed to women or all ages, in primary care, highlighting high risk patients

Could be used to track patients breast tissue response to medication

Micrima

Personalising Screening – to understand risk

Mi~Scan

Patient Questionnaire:

Integrating MiScan® density measurement with existing breast cancer risk models enables individual patient risk to be calculated on women of all ages, with high-risk women and breast types identified, within a community setting

Existing breast cancer risk models (currently can only include density with a Mammogram)

Ikonopedia®

Mi~Score



1. Patient data collected: MiScan®, patient questions, genetic test*
2. Risk Factors calculated adding MiScan® density to existing pre-validated models
3. Patient report indicates risk and breast tissue properties, and optimum pathway selection

*Not included in the MiScan measurement

Micrima

Where are we?

Today	CE MDR submitted to notified body for review Devices available for clinical trial, without CE mark but with independent safety and emissions testing and MHRA approval
2025	First deliveries and sales or MiScan® and MiScore expected to be available Autumn 2025, upon receipt of CE MDR approval
2026+	Rapid sales growth and adoption of the product for both density assessment, risk profiling and for tracking patient response to endocrine and anti-progestin therapies

Micrima

Micrima

Transforming detection of cancer for all women

sarah.magee@micrima.com

www.micrima.com